Development and Validation of a Noninvasive Score for At-Risk Metabolic Dysfunction-Associated Steatohepatitis in Individuals with Obesity Undergoing Bariatric Surgery
Posted inDiabetes & Endocrinology Gastroenterology news

Development and Validation of a Noninvasive Score for At-Risk Metabolic Dysfunction-Associated Steatohepatitis in Individuals with Obesity Undergoing Bariatric Surgery

Researchers developed and validated the FMO score, a noninvasive, cost-effective tool to identify at-risk metabolic dysfunction-associated steatohepatitis (MASH) in obese patients, showing strong predictive performance across multiple international cohorts.
Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data
Posted inDiabetes & Endocrinology news

Comparative 1-Year Outcomes of Semaglutide, Tirzepatide, and Sleeve Gastrectomy in Obese Adults with Type 2 Diabetes: Insights from Real-World Data

A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with surgery but varying safety profiles.
Tirzepatide Produced Broad 72-Week Improvements in Cardiovascular Risk Biomarkers Across Inflammatory, Metabolic, Endothelial, and Thrombotic Pathways in Obesity
Posted inCardiology Diabetes & Endocrinology news

Tirzepatide Produced Broad 72-Week Improvements in Cardiovascular Risk Biomarkers Across Inflammatory, Metabolic, Endothelial, and Thrombotic Pathways in Obesity

In a SURMOUNT-1 post hoc analysis, tirzepatide improved multiple cardiovascular risk biomarkers over 72 weeks in obesity, with the largest and most consistent effects seen for inflammation, insulin resistance, adiposity-related markers, endothelial dysfunction, and fibrinolytic balance.
Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial
Posted inDiabetes & Endocrinology news Psychiatry

Semaglutide Improves Insulin Sensitivity in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial

In a 30-week randomized trial, semaglutide improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and produced substantial weight loss in patients with schizophrenia and prediabetes taking second-generation antipsychotics.